This presentation represents consensus recommendations for the clinicopathological
definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction …

This presentation represents consensus recommendations on prognostic markers and
criteria to initiate therapy in patients with Waldenstrom's macroglobulinemia (WM), which …

Purpose Alkylating agents and the anti-CD20 monoclonal antibody rituximab are among
appropriate choices for the primary treatment of symptomatic patients with Waldenström …

Учебник подготовлен коллективом авторов-ведущими патофизиологами России и
стран СНГ (Украина, Грузия). В его создании принимали участие известные педагоги …

In this report we analyse the presenting features of a series of patients diagnosed with
Waldenström macroglobulinaemia (WM) in Spain over the last 10 years. Criteria for …

Purpose To review the diagnostic criteria, prognostic factors, response criteria, and
treatment options of patients with Waldenstrom's macroglobulinemia (WM). Methods A …

PURPOSE: Waldenström's macroglobulinemia (WM) is a low-grade lymphoplasmacytic
lymphoma in which CD20 is usually expressed on tumor cells. There is evidence that …

In the past 36 months, new developments have occurred both in the understanding of the
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …

Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration
in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in …

Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma
characterized by the presence of lymphoplasmacytic lymphoma (LPL) in the bone marrow …